Cancers, Vol. 11, Pages 1271: In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients
Cancers, Vol. 11, Pages 1271: In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients
Cancers doi: 10.3390/cancers11091271
Authors:
Heeke
Benzaquen
Long-Mira
Audelan
Lespinet
Bordone
Lalvée
Zahaf
Poudenx
Humbert
Montaudié
Dugourd
Chassang
Passeron
Delingette
Marquette
Hofman
Stenzinger
Ilié
Hofman
Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (R2 = 0.73) and melanoma (R2 = 0.94). The association of TMB with DCB was comparable between OTML (area-under the curve (AUC) = 0.67) and FO (AUC = 0.71) in NSCLC. Median TMB was higher in the DCB cohort and progression-free survival (PFS) was prolonged in patients with high TMB (OTML HR = 0.35; FO HR = 0.45). In contrast, we detected no dif...
Source: Cancers - Category: Cancer & Oncology Authors: Heeke Benzaquen Long-Mira Audelan Lespinet Bordone Lalv ée Zahaf Poudenx Humbert Montaudi é Dugourd Chassang Passeron Delingette Marquette Hofman Stenzinger Ili é Hofman Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Skin Cancer